$ELDN
Eledon Pharmaceuticals, Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018013090 Filed on May 11, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.700M $910.0K
YoY Change 86.81% -74.37%
% of Gross Profit
Research & Development $1.100M $306.0K
YoY Change 259.48% -96.14%
% of Gross Profit
Depreciation & Amortization $0.00 $17.00K
YoY Change -100.0% -67.92%
% of Gross Profit
Operating Expenses $2.795M $1.385M
YoY Change 101.81% -87.94%
Operating Profit -$2.795M -$1.385M
YoY Change 101.81% -87.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$11.00K $11.00K
YoY Change -200.0%
Pretax Income -$2.810M -$1.370M
YoY Change 105.11% -88.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.806M -$1.374M
YoY Change 104.22% -87.97%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$6.535M -$7.611M
COMMON SHARES
Basic Shares Outstanding 22.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.50M $24.40M
YoY Change -7.79% -55.06%
Cash & Equivalents $22.52M $24.40M
Short-Term Investments $0.00
Other Short-Term Assets $17.00K $1.200M
YoY Change -98.58% -55.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.00M $25.63M
YoY Change -6.36% -55.02%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $80.00K
YoY Change -100.0% -82.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K
YoY Change -66.67%
Total Long-Term Assets $1.900M $200.0K
YoY Change 850.0% -72.34%
TOTAL ASSETS
Total Short-Term Assets $24.00M $25.63M
Total Long-Term Assets $1.900M $200.0K
Total Assets $25.90M $25.83M
YoY Change 0.27% -55.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $276.0K
YoY Change 44.93% -85.37%
Accrued Expenses $1.200M $2.143M
YoY Change -44.0% -50.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.600M $2.419M
YoY Change -33.86% -60.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $48.00K
YoY Change -100.0% -61.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.600M $2.419M
Total Long-Term Liabilities $0.00 $48.00K
Total Liabilities $1.600M $2.467M
YoY Change -35.14% -60.86%
SHAREHOLDERS EQUITY
Retained Earnings -$173.3M
YoY Change 21.28%
Common Stock $196.6M
YoY Change 1.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.30M $23.36M
YoY Change
Total Liabilities & Shareholders Equity $25.90M $25.83M
YoY Change 0.27% -55.24%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.806M -$1.374M
YoY Change 104.22% -87.97%
Depreciation, Depletion And Amortization $0.00 $17.00K
YoY Change -100.0% -67.92%
Cash From Operating Activities -$2.271M -$3.150M
YoY Change -27.9% -67.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.330M
YoY Change -100.0%
Cash From Investing Activities $0.00 $4.330M
YoY Change -100.0% -21750.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.491M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.491M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.271M -3.150M
Cash From Investing Activities 0.000 4.330M
Cash From Financing Activities 7.491M 0.000
Net Change In Cash 5.220M -482.0K
YoY Change -1182.99% -95.04%
FREE CASH FLOW
Cash From Operating Activities -$2.271M -$3.150M
Capital Expenditures $0.00
Free Cash Flow -$3.150M
YoY Change -67.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17303000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1117000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22523000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
635000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1698000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
906000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2795000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1385000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2795000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1385000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2806000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1374000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7749263
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
413635
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
161000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
106000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-192000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
179000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
375000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2271000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-882000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7491000
CY2017Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
400000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7491000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
400000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5220000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-482000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.86%;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to stock-based compensation, accruals for liabilities, carrying value of goodwill, and other matters that affect the condensed consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements. </p></div>
CY2018Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
118000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
161000
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
17000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18000
CY2018Q1 nvus Accrued Clinical Current
AccruedClinicalCurrent
105000
CY2017Q4 nvus Accrued Clinical Current
AccruedClinicalCurrent
85000
CY2018Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
39000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
372000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
158000
CY2018Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
138000
CY2017Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
840115
CY2018Q1 nvus Working Capital
WorkingCapital
22400000
CY2018Q1 nvus Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2018Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2017Q1 nvus Interest Accumulated On Preferred Shares And Contingently Issuable For Little Or No Cash
InterestAccumulatedOnPreferredSharesAndContingentlyIssuableForLittleOrNoCash
229000
CY2017Q1 nvus Net Income Loss Attributable To Shareholders Of Preferred Shares And Contingently Issuable For Little Or No Cash
NetIncomeLossAttributableToShareholdersOfPreferredSharesAndContingentlyIssuableForLittleOrNoCash
1357000
CY2018Q1 nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-2806000
CY2017Q1 nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-246000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
816766
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58039
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q1 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
CY2018Q1 nvus Income Tax Examination Likelihood Of Favorable Settlement
IncomeTaxExaminationLikelihoodOfFavorableSettlement
0.50
CY2017Q1 nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
785000
CY2017Q1 nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
2882000
CY2017Q1 nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
3667000
CY2017Q1 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-3667000
CY2017Q1 nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
37000
CY2017Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-3630000
CY2017Q1 nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-0.54
CY2017Q1 nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6686141
CY2018Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1370000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1518000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
111000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88000
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
42000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
41000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
130000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
187000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
195000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
152000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
664000
CY2018Q1 nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2017 nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2018Q1 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2018Q1 nvus Contingent Liability
ContingentLiability
0
CY2017 nvus Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35

Files In Submission

Name View Source Status
0001564590-18-013090-index-headers.html Edgar Link pending
0001564590-18-013090-index.html Edgar Link pending
0001564590-18-013090.txt Edgar Link pending
0001564590-18-013090-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nvus-10q_20180331.htm Edgar Link pending
nvus-20180331.xml Edgar Link completed
nvus-20180331.xsd Edgar Link pending
nvus-20180331_cal.xml Edgar Link unprocessable
nvus-20180331_def.xml Edgar Link unprocessable
nvus-20180331_lab.xml Edgar Link unprocessable
nvus-20180331_pre.xml Edgar Link unprocessable
nvus-ex311_8.htm Edgar Link pending
nvus-ex312_6.htm Edgar Link pending
nvus-ex321_9.htm Edgar Link pending
nvus-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending